Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
MRNA · NASDAQ · Biotechnology
$195.00−4.33 (−2.17%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Moderna (MRNA) · oqro.io/stocks/MRNA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Insider trade · Traded Nov 16, 2026 · Filed Nov 18, 2026
Officer sold ~$8.6M of MRNA shares in the open marketSourceInsider trade · Traded Nov 17, 2026 · Filed Nov 18, 2026
Officer sold ~$7.18M of MRNA shares in the open marketSourceInsider trade · Traded Nov 17, 2026 · Filed Nov 18, 2026
Officer sold ~$1.08M of MRNA shares in the open marketSourceInsider trade · Traded Nov 17, 2026 · Filed Nov 18, 2026
Officer sold ~$34K of MRNA shares in the open marketSourcePlanned sale · Planned for Nov 17, 2026 · Notice filed Nov 17, 2026
Officer filed to sell about $8.3M of MRNA stockSourcePlanned sale · Planned for Nov 16, 2026 · Notice filed Nov 16, 2026
Officer filed to sell about $8.6M of MRNA stockSourceFund moves · Holdings as of Sep 30, 2026 (Q3 2026) · Filed Nov 16, 2026
Bridgewater Associates disclosed an increased position in MRNA for Q3 2026SourcePolitician trade (House) · Transaction Oct 20, 2026 · Disclosed Nov 10, 2026
Disclosed purchase of MRNA — reported range $1,001 - $15,000SourceInsider trade · Traded Oct 15, 2026 · Filed Oct 16, 2026
Officer sold ~$8.64M of MRNA shares in the open marketSourceInsider trade · Traded Oct 14, 2026 · Filed Oct 16, 2026
Officer sold ~$8.28M of MRNA shares in the open marketSourceInsider trade · Traded Oct 14, 2026 · Filed Oct 16, 2026
Officer sold ~$96K of MRNA shares in the open marketSourcePlanned sale · Planned for Oct 15, 2026 · Notice filed Oct 15, 2026
Officer filed to sell about $8.64M of MRNA stockSourceInsider trade · Traded Sep 15, 2026 · Filed Sep 16, 2026
Officer sold ~$5.88M of MRNA shares in the open marketSourceInsider trade · Traded Sep 14, 2026 · Filed Sep 16, 2026
Officer sold ~$5.81M of MRNA shares in the open marketSourcePlanned sale · Planned for Sep 15, 2026 · Notice filed Sep 15, 2026
Officer filed to sell about $5.88M of MRNA stockSourceInsider trade · Traded Sep 10, 2026 · Filed Sep 14, 2026
CFO sold ~$2.67M of MRNA shares in the open marketSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Alyeska Investment Group, L.P. disclosed a reduced position in MRNA for Q2 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Bridgewater Associates disclosed a reduced position in MRNA for Q2 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 13, 2026
Letko, Brosseau & Associates Inc disclosed a reduced position in MRNA for Q2 2026Source5%+ stake · Stake as of Jun 30, 2026 · Filed Aug 12, 2026
Capital World Investors now owns 5.6% of MRNA as a passive investor5%+ stake · Stake as of Jun 30, 2026 · Filed Jul 24, 2026
BAILLIE GIFFORD & CO cut its MRNA stake below 5% (4.6%)SourceInsider trade · Traded Jul 15, 2026 · Filed Jul 16, 2026
Officer sold ~$3.61M of MRNA shares in the open marketSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Jul 14, 2026
Douglas Lane & Associates, LLC disclosed an increased position in MRNA for Q2 2026SourceInsider trade · Traded Jun 15, 2026 · Filed Jun 17, 2026
Officer sold ~$2.74M of MRNA shares in the open marketSourceInsider trade · Traded Jun 4, 2026 · Filed Jun 8, 2026
Officer sold ~$174K of MRNA shares in the open marketSourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 29, 2026
Perceptive Advisors LLC disclosed a new position in MRNA (put options) for Q1 2026SourceInsider trade · Traded May 21, 2026 · Filed May 22, 2026
Director sold ~$434K of MRNA shares in the open marketSourceInsider trade · Traded May 15, 2026 · Filed May 18, 2026
Officer sold ~$2.58M of MRNA shares in the open marketSourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed May 15, 2026
Coatue Management disclosed a new position in MRNA for Q4 2025SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed Apr 15, 2026
Douglas Lane & Associates, LLC disclosed an increased position in MRNA for Q1 2026SourceInsider trade · Traded Mar 2, 2026 · Filed Mar 3, 2026
Officer sold ~$726K of MRNA shares in the open marketSourceInsider trade · Traded Feb 23, 2026 · Filed Feb 25, 2026
Officer sold ~$7.81M of MRNA shares in the open marketSourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 13, 2026
Alyeska Investment Group, L.P. disclosed a new position in MRNA for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 13, 2026
Bridgewater Associates disclosed a reduced position in MRNA for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 11, 2026
Letko, Brosseau & Associates Inc disclosed a reduced position in MRNA for Q4 2025Fund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Jan 23, 2026
Baillie Gifford & Co disclosed a reduced position in MRNA for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Jan 22, 2026
Douglas Lane & Associates, LLC disclosed an increased position in MRNA for Q4 2025SourceInsider trade · Traded Dec 11, 2025 · Filed Dec 15, 2025
Director sold ~$703K of MRNA shares in the open marketSourceInsider trade · Traded Dec 9, 2025 · Filed Dec 11, 2025
Director sold ~$14K of MRNA shares in the open marketSourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 14, 2025
Deerfield Management Company, L.P. disclosed a new position in MRNA (put options) for Q3 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 14, 2025
Deerfield Management Company, L.P. no longer reported MRNA for Q3 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 14, 2025
Montanova Capital, LLC no longer reported MRNA for Q3 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 14, 2025
Bellevue Group AG disclosed a reduced position in MRNA for Q3 2025Fund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Oct 31, 2025
Baillie Gifford & Co disclosed a reduced position in MRNA for Q3 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Oct 21, 2025
Bank Pictet & Cie (Europe) AG disclosed a reduced position in MRNA for Q3 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Oct 10, 2025
Douglas Lane & Associates, LLC disclosed an increased position in MRNA for Q3 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Deerfield Management Company, L.P. disclosed a new position in MRNA for Q2 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed Aug 14, 2025
Farallon Capital Management, L.L.C. no longer reported MRNA (put options) for Q1 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Bellevue Group AG disclosed a reduced position in MRNA for Q2 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Voloridge Investment Management, LLC disclosed an increased position in MRNA for Q2 2025Fund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Jul 16, 2025
Bank Pictet & Cie (Europe) AG disclosed an increased position in MRNA for Q2 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Jul 7, 2025
Douglas Lane & Associates, LLC disclosed an increased position in MRNA for Q2 2025SourceInsider trade · Traded Jun 11, 2025 · Filed Jun 12, 2025
Director sold ~$8.7K of MRNA shares in the open marketSourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 15, 2025
Sessa Capital IM, L.P. disclosed a new position in MRNA for Q1 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 15, 2025
Montanova Capital, LLC disclosed a new position in MRNA for Q1 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 15, 2025
Coatue Management no longer reported MRNA for Q1 2025SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed May 15, 2025
Farallon Capital Management, L.L.C. disclosed a reduced position in MRNA (put options) for Q4 2024Fund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed Apr 9, 2025
Douglas Lane & Associates, LLC disclosed an increased position in MRNA for Q1 2025SourcePolitician trade (House) · Transaction Feb 25, 2025 · Disclosed Mar 27, 2025
Disclosed purchase of MRNA — reported range $1,001 - $15,000SourceInsider trade · Traded Mar 3, 2025 · Filed Mar 4, 2025
CEO purchased ~$3.19M of MRNA shares in the open marketSourceInsider trade · Traded Mar 3, 2025 · Filed Mar 4, 2025
CEO purchased ~$1.81M of MRNA shares in the open marketSourceInsider trade · Traded Mar 3, 2025 · Filed Mar 4, 2025
Director purchased ~$1M of MRNA shares in the open marketSourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Coatue Management disclosed a new position in MRNA for Q4 2024SourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Feb 14, 2025
Farallon Capital Management, L.L.C. disclosed an increased position in MRNA (put options) for Q3 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Letko, Brosseau & Associates Inc disclosed an increased position in MRNA for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Voloridge Investment Management, LLC disclosed an increased position in MRNA for Q4 2024Planned sale · Planned for Oct 14, 2026 · Notice filed Oct 14, 2026
Officer filed to sell about $8.37M of MRNA stockSourcePolitician trade (House) · Transaction Sep 24, 2026 · Disclosed Oct 7, 2026
Disclosed partial sale of MRNA — reported range $1,001 - $15,000SourceInsider trade · Traded Sep 10, 2026 · Filed Sep 14, 2026
CFO sold ~$2.02M of MRNA shares in the open marketSourcePlanned sale · Planned for Sep 14, 2026 · Notice filed Sep 14, 2026
Officer filed to sell about $5.81M of MRNA stockSourcePlanned sale · Planned for Sep 10, 2026 · Notice filed Sep 10, 2026
Officer filed to sell about $4.69M of MRNA stockSourcePolitician trade (House) · Transaction Aug 19, 2026 · Disclosed Sep 9, 2026
Disclosed partial sale of MRNA — reported range $1,001 - $15,000SourcePolitician trade (House) · Transaction Aug 19, 2026 · Disclosed Sep 9, 2026
Disclosed purchase of MRNA — reported range $1,001 - $15,000SourceInsider trade · Traded Sep 1, 2026 · Filed Sep 3, 2026
Officer sold ~$486K of MRNA shares in the open marketSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$11M of MRNA shares in the open marketSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$8.29M of MRNA shares in the open marketSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$7.11M of MRNA shares in the open marketSourceInsider trade · Traded Aug 5, 2026 · Filed Aug 7, 2026
CEO sold ~$2.32M of MRNA shares in the open marketSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 6, 2026
Baillie Gifford & Co disclosed a reduced position in MRNA for Q2 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Coatue Management no longer reported MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Bridgewater Associates disclosed an increased position in MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Deerfield Management Company, L.P. no longer reported MRNA (put options) for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Sessa Capital IM, L.P. no longer reported MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Alyeska Investment Group, L.P. disclosed an increased position in MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 14, 2026
Lingotto Investment Management LLP disclosed an increased position in MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 12, 2026
Letko, Brosseau & Associates Inc disclosed an increased position in MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 8, 2026
Baillie Gifford & Co disclosed a reduced position in MRNA for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 5, 2026
OFI Invest Asset Management disclosed an increased position in MRNA for Q1 2026SourceInsider trade · Traded May 1, 2026 · Filed May 4, 2026
Director sold ~$265K of MRNA shares in the open marketSourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 10, 2026
Lingotto Investment Management LLP disclosed a reduced position in MRNA for Q4 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 14, 2025
Voloridge Investment Management, LLC disclosed a reduced position in MRNA for Q3 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 13, 2025
Bridgewater Associates disclosed a new position in MRNA for Q3 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 8, 2025
Letko, Brosseau & Associates Inc disclosed an increased position in MRNA for Q2 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 6, 2025
Baillie Gifford & Co disclosed a reduced position in MRNA for Q2 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 15, 2025
Voloridge Investment Management, LLC disclosed an increased position in MRNA for Q1 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 14, 2025
Bridgewater Associates no longer reported MRNA for Q1 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 14, 2025
Bellevue Group AG disclosed a reduced position in MRNA for Q1 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 8, 2025
Letko, Brosseau & Associates Inc disclosed a reduced position in MRNA for Q1 2025SourcePolitician trade (House) · Transaction Apr 8, 2025 · Disclosed May 8, 2025
Disclosed sale of MRNA — reported range $1,001 - $15,000SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 7, 2025
Baillie Gifford & Co disclosed a reduced position in MRNA for Q1 2025Source